Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

McMaster University

$151,492.00

Rational engineering of antibiotic production

FY 2008-09

Summary
The "Streptomyces" bacteria exhibit a complex "secondary" or non-essential metabolism, producing small molecules called "natural products". As part of this process, the streptomycetes produce chemotherapeutic agents, anti-fungal drugs, immune suppressants used to prevent transplant rejection, herbicides, anti-helminthic drugs, and most notably the majority of the antibiotics in current clinical and agricultural use. New species of Streptomyces are easy to isolate from the soil but their secondary metabolites are produced in minute quantities under laboratory conditions: many cannot be detected at all. Research into secondary metabolism has provided us with a list of genes that, if over-expressed, could dramatically increase secondary metabolism. Our goal is to exploit these genes to produce "universal activators" of antibiotic production that can be used to maximize output in any streptomycete. In partnership with JNE Biotech Inc. we will develop this resource for use in the enhanced production of known drugs and the discovery of new drugs. Our short term goals are to 1. identify as many of the genes in the species S. coelicolor and S. griseus that can stimulate increased antibiotic production and 2. find ways of amplifying production of streptomycin and spectinomycin, and eventually other antibiotics, chemotherapeutic agents and anti-parasitic drugs produced by streptomycetes. Over the longer term we aim to apply these tools in uncharacterised streptomycetes to identify new agents capable of inhibiting/killing infectious microbes, parasites and tumour cells. This work will strengthen the Streptomyces research field by increasing our understanding antibiotic production. Benefits to Canada from this work will include the training of graduate students and postdoctoral fellows in sophisticated recombinant DN A and mass spectrometry technology. Furthermore, by enhancing our ability to produce known antibiotics and discover new secondary metabolites, we will strengthen biotechnology in Canada and facilitate the growth of a local biotechnology company (JNE Biotech Inc.). This will result in increased employment in the pharmaceutical sector in Hamilton.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
335144-2005
Name nom
Nodwell, Justin
Department département
Biochemistry and Biomedical Sciences
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2005
Award amount
151492
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
3 & 4
Nb partie
4
Application title
Rational engineering of antibiotic production
Keyword
NA
Application summary
The "Streptomyces" bacteria exhibit a complex "secondary" or non-essential metabolism, producing small molecules called "natural products". As part of this process, the streptomycetes produce chemotherapeutic agents, anti-fungal drugs, immune suppressants used to prevent transplant rejection, herbicides, anti-helminthic drugs, and most notably the majority of the antibiotics in current clinical and agricultural use. New species of Streptomyces are easy to isolate from the soil but their secondary metabolites are produced in minute quantities under laboratory conditions: many cannot be detected at all. Research into secondary metabolism has provided us with a list of genes that, if over-expressed, could dramatically increase secondary metabolism. Our goal is to exploit these genes to produce "universal activators" of antibiotic production that can be used to maximize output in any streptomycete. In partnership with JNE Biotech Inc. we will develop this resource for use in the enhanced production of known drugs and the discovery of new drugs. Our short term goals are to 1. identify as many of the genes in the species S. coelicolor and S. griseus that can stimulate increased antibiotic production and 2. find ways of amplifying production of streptomycin and spectinomycin, and eventually other antibiotics, chemotherapeutic agents and anti-parasitic drugs produced by streptomycetes. Over the longer term we aim to apply these tools in uncharacterised streptomycetes to identify new agents capable of inhibiting/killing infectious microbes, parasites and tumour cells. This work will strengthen the Streptomyces research field by increasing our understanding antibiotic production. Benefits to Canada from this work will include the training of graduate students and postdoctoral fellows in sophisticated recombinant DN A and mass spectrometry technology. Furthermore, by enhancing our ability to produce known antibiotics and discover new secondary metabolites, we will strengthen biotechnology in Canada and facilitate the growth of a local biotechnology company (JNE Biotech Inc.). This will result in increased employment in the pharmaceutical sector in Hamilton.